These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 20403481)

  • 1. Relation of different measures of low-density lipoprotein cholesterol to risk of coronary artery disease and death in a meta-regression analysis of large-scale trials of statin therapy.
    Kizer JR; Madias C; Wilner B; Vaughan CJ; Mushlin AI; Trushin P; Gotto AM; Pasternak RC
    Am J Cardiol; 2010 May; 105(9):1289-96. PubMed ID: 20403481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis.
    Nicholls SJ; Tuzcu EM; Sipahi I; Grasso AW; Schoenhagen P; Hu T; Wolski K; Crowe T; Desai MY; Hazen SL; Kapadia SR; Nissen SE
    JAMA; 2007 Feb; 297(5):499-508. PubMed ID: 17284700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
    Baigent C; Keech A; Kearney PM; Blackwell L; Buck G; Pollicino C; Kirby A; Sourjina T; Peto R; Collins R; Simes R;
    Lancet; 2005 Oct; 366(9493):1267-78. PubMed ID: 16214597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials.
    Josan K; Majumdar SR; McAlister FA
    CMAJ; 2008 Feb; 178(5):576-84. PubMed ID: 18299547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The beneficial effects of raising high-density lipoprotein cholesterol depends upon achieved levels of low-density lipoprotein cholesterol during statin therapy: Implications for coronary atheroma progression and cardiovascular events.
    Puri R; Nissen SE; Shao M; Kataoka Y; Uno K; Kapadia SR; Tuzcu EM; Nicholls SJ
    Eur J Prev Cardiol; 2016 Mar; 23(5):474-85. PubMed ID: 25691546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the Association Between Low-Density Lipoprotein Cholesterol Reduction and Relative and Absolute Effects of Statin Treatment: A Systematic Review and Meta-analysis.
    Byrne P; Demasi M; Jones M; Smith SM; O'Brien KK; DuBroff R
    JAMA Intern Med; 2022 May; 182(5):474-481. PubMed ID: 35285850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of non-statin lipid-lowering therapy in coronary atherosclerosis regression: a meta-analysis and meta-regression.
    Masson W; Lobo M; Siniawski D; Molinero G; Masson G; Huerín M; Nogueira JP
    Lipids Health Dis; 2020 May; 19(1):111. PubMed ID: 32460779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Industry sponsorship bias in research findings: a network meta-analysis of LDL cholesterol reduction in randomised trials of statins.
    Naci H; Dias S; Ades AE
    BMJ; 2014 Oct; 349():g5741. PubMed ID: 25281681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials.
    Marston NA; Giugliano RP; Im K; Silverman MG; O'Donoghue ML; Wiviott SD; Ference BA; Sabatine MS
    Circulation; 2019 Oct; 140(16):1308-1317. PubMed ID: 31530008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD): A Randomized Superiority Trial.
    Taguchi I; Iimuro S; Iwata H; Takashima H; Abe M; Amiya E; Ogawa T; Ozaki Y; Sakuma I; Nakagawa Y; Hibi K; Hiro T; Fukumoto Y; Hokimoto S; Miyauchi K; Yamazaki T; Ito H; Otsuji Y; Kimura K; Takahashi J; Hirayama A; Yokoi H; Kitagawa K; Urabe T; Okada Y; Terayama Y; Toyoda K; Nagao T; Matsumoto M; Ohashi Y; Kaneko T; Fujita R; Ohtsu H; Ogawa H; Daida H; Shimokawa H; Saito Y; Kimura T; Inoue T; Matsuzaki M; Nagai R
    Circulation; 2018 May; 137(19):1997-2009. PubMed ID: 29735587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atheroma progression in hyporesponders to statin therapy.
    Kataoka Y; St John J; Wolski K; Uno K; Puri R; Tuzcu EM; Nissen SE; Nicholls SJ
    Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):990-5. PubMed ID: 25722430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical and psychosocial factors and unfavourable low-density lipoprotein cholesterol control in coronary patients.
    Munkhaugen J; Sverre E; Otterstad JE; Peersen K; Gjertsen E; Perk J; Gullestad L; Moum T; Dammen T; Husebye E
    Eur J Prev Cardiol; 2017 Jun; 24(9):981-989. PubMed ID: 28196429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.
    Nissen SE; Tuzcu EM; Schoenhagen P; Crowe T; Sasiela WJ; Tsai J; Orazem J; Magorien RD; O'Shaughnessy C; Ganz P;
    N Engl J Med; 2005 Jan; 352(1):29-38. PubMed ID: 15635110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Robust association of the LPA locus with low-density lipoprotein cholesterol lowering response to statin treatment in a meta-analysis of 30 467 individuals from both randomized control trials and observational studies and association with coronary artery disease outcome during statin treatment.
    Donnelly LA; van Zuydam NR; Zhou K; Tavendale R; Carr F; Maitland-van der Zee AH; Leusink M; de Boer A; Doevendans PA; Asselbergs FW; Morris AD; Pearson ER; Klungel OH; Doney AS; Palmer CN
    Pharmacogenet Genomics; 2013 Oct; 23(10):518-25. PubMed ID: 23903772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensive reduction of low-density lipoprotein-cholesterol: implications of recent trials.
    Hackam DG
    Am J Cardiovasc Drugs; 2006; 6(6):367-71. PubMed ID: 17192126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial.
    Vallejo-Vaz AJ; Fayyad R; Boekholdt SM; Hovingh GK; Kastelein JJ; Melamed S; Barter P; Waters DD; Ray KK
    Circulation; 2018 Aug; 138(8):770-781. PubMed ID: 29618599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
    Tani S; Nagao K; Hirayama A
    Am J Cardiovasc Drugs; 2011 Dec; 11(6):411-7. PubMed ID: 22149320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
    Nicholls SJ; Puri R; Anderson T; Ballantyne CM; Cho L; Kastelein JJ; Koenig W; Somaratne R; Kassahun H; Yang J; Wasserman SM; Scott R; Ungi I; Podolec J; Ophuis AO; Cornel JH; Borgman M; Brennan DM; Nissen SE
    JAMA; 2016 Dec; 316(22):2373-2384. PubMed ID: 27846344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.